HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Akihiro Kawauchi Selected Research

4- (4- cyclohexyl- 2- methyloxazol- 5- yl)- 2- fluorobenzenesulfonamide

1/2010Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522.
10/2004Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.
12/2002Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Akihiro Kawauchi Research Topics

Disease

51Neoplasms (Cancer)
01/2022 - 09/2002
27Prostatic Neoplasms (Prostate Cancer)
07/2021 - 05/2003
25Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 03/2003
13Urinary Bladder Neoplasms (Bladder Cancer)
07/2021 - 03/2002
9Neoplasm Metastasis (Metastasis)
01/2022 - 12/2004
6Carcinoma (Carcinomatosis)
01/2022 - 10/2004
6Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
08/2016 - 05/2006
5Adenocarcinoma
07/2021 - 07/2005
5Nocturnal Enuresis (Bedwetting)
11/2012 - 12/2002
4Hemorrhage
11/2014 - 03/2003
3Hypoxia (Hypoxemia)
01/2022 - 02/2011
3Enuresis
02/2020 - 12/2006
3Testicular Neoplasms (Testicular Cancer)
11/2019 - 02/2006
3Convalescence
05/2018 - 09/2002
3Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
10/2017 - 07/2005
2Thrombocytopenia (Thrombopenia)
07/2021 - 08/2015
2Non-Muscle Invasive Bladder Neoplasms
03/2021 - 01/2018
2Margins of Excision
01/2021 - 06/2012
2Erectile Dysfunction
12/2020 - 11/2007
2Fatigue
01/2020 - 08/2015
2Diarrhea
01/2020 - 01/2016
2Vesico-Ureteral Reflux (Vesicoureteral Reflux)
01/2019 - 11/2009
2Breast Neoplasms (Breast Cancer)
01/2019 - 09/2016
2Overactive Urinary Bladder (Overactive Bladder)
10/2017 - 11/2011
2Hypersensitivity (Allergy)
06/2007 - 01/2004
1Lung Neoplasms (Lung Cancer)
01/2022
1Exanthema (Rash)
09/2021
1Erythema Multiforme
09/2021
1Acne Vulgaris
09/2021
1Hand-Foot Syndrome
09/2021
1Disease Progression
07/2021

Drug/Important Bio-Agent (IBA)

9Proteins (Proteins, Gene)FDA Link
01/2022 - 03/2003
9AndrogensIBA
07/2021 - 06/2007
8EnzymesIBA
01/2022 - 12/2002
7Cisplatin (Platino)FDA LinkGeneric
11/2019 - 10/2004
6Pharmaceutical PreparationsIBA
01/2022 - 01/2005
6Antineoplastic Agents (Antineoplastics)IBA
01/2010 - 12/2002
6Fluorouracil (Carac)FDA LinkGeneric
09/2008 - 03/2002
5Messenger RNA (mRNA)IBA
01/2022 - 12/2002
5Prostate-Specific Antigen (Semenogelase)IBA
07/2021 - 07/2004
5Biomarkers (Surrogate Marker)IBA
10/2020 - 01/2013
4Androgen Receptors (Androgen Receptor)IBA
01/2020 - 01/2006
4Docetaxel (Taxotere)FDA Link
09/2019 - 02/2006
4gamma-GlutamylcyclotransferaseIBA
01/2019 - 01/2015
4LigandsIBA
01/2013 - 09/2006
3Transcription Factors (Transcription Factor)IBA
01/2022 - 01/2016
3Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric
02/2020 - 05/2004
3nedaplatinIBA
02/2019 - 05/2006
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2013 - 09/2006
3Liposomes (Liposome)IBA
05/2012 - 03/2003
34- (4- cyclohexyl- 2- methyloxazol- 5- yl)- 2- fluorobenzenesulfonamideIBA
01/2010 - 12/2002
3Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
01/2010 - 12/2002
3Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2010 - 12/2002
3ProstaglandinsIBA
01/2010 - 12/2002
3Paclitaxel (Taxol)FDA LinkGeneric
10/2009 - 02/2006
2Glutathione (Reduced Glutathione)IBA
01/2022 - 07/2018
2NivolumabIBA
09/2021 - 01/2020
2bicalutamide (Casodex)FDA LinkGeneric
07/2021 - 01/2019
22- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
07/2021 - 01/2004
2Phosphodiesterase 5 InhibitorsIBA
12/2020 - 10/2017
2Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2019 - 09/2016
2Small Interfering RNA (siRNA)IBA
01/2018 - 09/2013
2CyclinsIBA
01/2018 - 12/2016
2Cholinergic Antagonists (Anticholinergics)IBA
10/2017 - 11/2011
2Sunitinib (Sutent)FDA Link
09/2016 - 08/2015
2Tumor Biomarkers (Tumor Markers)IBA
08/2016 - 10/2002
2GemcitabineFDA Link
10/2009 - 02/2006
2Androgen Antagonists (Antiandrogens)IBA
06/2007 - 02/2007
2Thymidylate SynthaseIBA
05/2007 - 03/2002
2Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA
03/2007 - 03/2002
2Indicators and Reagents (Reagents)IBA
10/2002 - 03/2002
1Indocyanine Green (Cardio-Green)FDA LinkGeneric
01/2022
1Antisense OligonucleotidesIBA
01/2022
1Sorafenib (BAY 43-9006)FDA Link
09/2021
1abirateroneIBA
07/2021
1EstramustineFDA Link
07/2021
1Flutamide (Eulexin)FDA LinkGeneric
07/2021
1taxaneIBA
07/2021
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
07/2021

Therapy/Procedure

22Therapeutics
07/2021 - 12/2002
14Nephrectomy
01/2022 - 09/2002
11Drug Therapy (Chemotherapy)
11/2019 - 02/2006
7Prostatectomy (Retropubic Prostatectomy)
05/2018 - 07/2005
5Radiofrequency Ablation
11/2009 - 12/2004
3Castration
07/2021 - 01/2011
3Conservative Treatment
10/2017 - 01/2003
3Lymph Node Excision (Lymph Node Dissection)
08/2016 - 04/2009
3Radiotherapy
01/2013 - 10/2009
3Aftercare (After-Treatment)
11/2012 - 12/2002
2Warm Ischemia
01/2021 - 11/2014
2Molecular Targeted Therapy
01/2019 - 06/2012
2Orchiectomy (Orchidectomy)
01/2016 - 08/2013
2Surgical Instruments (Clip)
08/2015 - 11/2014
2Combined Modality Therapy
03/2015 - 11/2009
2Brachytherapy
03/2014 - 07/2012
2Conversion to Open Surgery
08/2013 - 03/2003
2Operative Time
06/2012 - 06/2009
2Blood Transfusion (Blood Transfusions)
07/2011 - 12/2004
2Immunotherapy
09/2008 - 03/2003
2Nephroureterectomy
01/2004 - 03/2003